Articles

TCAR (Transcarotid Artery Revascularization): The Next Step in the Evolution of Carotid Revascularization.

Jeffrey Jim, MD, MPHS, FACS
Supplement to Endovascular Today, August 2018

Optimal Pharmacologic Strategy for TCAR: An Expert Panel Discussion.

Michael R. Jaff, DO; Sumaira Macdonald, MBChB (Comm), MD, FRCP, FRCR, PhD; Richard Cambria, MD; Nathan J. Aranson, MD; Angela A. Kokkosis, MD; Herbert D. Aronow, MD, MPH; and Edgar D. Guzman, MD, FACS, RPVI
Supplement to Endovascular Today, August 2018

Periprocedural Hemodynamic Management for Transcarotid Artery Revascularization.

Michael R. Jaff, DO; Angela A. Kokkosis, MD; José Ignacio Leal, MD, PhD; and Sumaira Macdonald, MBChB (Comm), MD, FRCP, FRCR, PhD
Supplement to Endovascular Today, August 2018

Reimbursement and Future Coverage for Transcarotid Artery Revascularization.

Louis Jacques, MD; and Marc L. Schermerhorn, MD
Supplement to Endovascular Today, August 2018

Transcervical carotid stenting with dynamic flow reversal demonstrates embolisation rates comparable to carotid endarterectomy*

Maarten Plessers, MSc
Vascular News, April 2016

Is CAS a Reasonable Alternative to CEA?

Wesley Moore, MD
Vascular Specialist April 2016 page 2

Avoiding the Aortic Arch and Using Flow Reversal: Carotid Artery Stenting with the Silk Road System to Reduce Stroke.

Richard Cambria, MD. Cath Lab Digest. 2014. April: 22(4):12,14

An Overview of the ROADSTER Trial.

Christopher J. Kwolek, MD, and Richard M. Ruedy. Endovascular Today. 2013. Sept.

* The ENROUTE NPS and Stent Systems are approved for use in the EU in patients at standard risk for complications from CEA. These indications have not been evaluated by the US FDA.
The links on this page take you away from the Silk Road Medical website. These websites are not operated by Silk Road Medical. Silk Road Medical does not control the content of these websites.